Endologix (NASDAQ: ELGX) and ConforMIS (NASDAQ:CFMS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.

Volatility & Risk

Endologix has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, ConforMIS has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500.


This table compares Endologix and ConforMIS’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Endologix -40.77% -46.32% -13.67%
ConforMIS -72.87% -66.61% -49.87%

Earnings & Valuation

This table compares Endologix and ConforMIS’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Endologix $190.75 million 1.87 -$54.38 million ($0.94) -4.55
ConforMIS $79.26 million 2.03 -$54.78 million ($1.36) -2.64

Endologix has higher revenue and earnings than ConforMIS. Endologix is trading at a lower price-to-earnings ratio than ConforMIS, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

39.5% of ConforMIS shares are owned by institutional investors. 3.9% of Endologix shares are owned by company insiders. Comparatively, 9.6% of ConforMIS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Endologix and ConforMIS, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Endologix 0 10 0 0 2.00
ConforMIS 0 4 3 0 2.43

Endologix currently has a consensus target price of $6.33, indicating a potential upside of 47.98%. ConforMIS has a consensus target price of $8.25, indicating a potential upside of 129.81%. Given ConforMIS’s stronger consensus rating and higher possible upside, analysts clearly believe ConforMIS is more favorable than Endologix.


ConforMIS beats Endologix on 7 of the 13 factors compared between the two stocks.

About Endologix

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.

About ConforMIS

ConforMIS, Inc. is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints. It offers a line of customized knee implants designed to restore the natural shape of a patient’s knee. It offers iTotal CR, which is a total knee replacement implant. Its iFit technology platform consists of three elements, including iFit Design, its algorithms and computer software that is used to design customized implants and associated single-use patient-specific instrumentation referred to as iJigs, based on computed tomography scans of the patient and to prepare a surgical plan customized for the patient (iView); iFit Printing, which is a three-dimensional printing technology used to manufacture iJigs, and iFit Just-in-Time manufacturing and delivery capabilities.

Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.